The Cleveland Clinic
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, The Cleveland Clinic sits in the top decile of US sponsors by registered trial count (#50 of 15,742 sponsors by registered trial count).
The Cleveland Clinic: 688 sponsored US clinical trials, 99 recruiting.
The Cleveland Clinic sponsors 688 registered US clinical trials on ClinicalTrials.gov, 99 of them currently recruiting, and 437 completed. 81 of these trials are in Phase 3-4 (later-stage) and 76 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atrial Fibrillation, with 9 trials.
Top-decile sponsor footprint
The Cleveland Clinic ranks in the top decile of sponsors by registered trial count (#50 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
437 of 539 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
688 total, page 14 of 14
Reiki/Energy Healing in Prostate Cancer
NCT00065208
Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
NCT01231841
Study Comparing Tension-free Vaginal Tape With the Monarc Procedure for Stress Urinary Incontinence
NCT00475839
Dexmed/Buspirone Synergism on Shivering
NCT00334360
Improving Influenza Vaccination Rates Among Health Care Professionals
NCT00404664
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
NCT00403169
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
NCT00401128
Safety Monitoring of Patients Having Pulmonary Vein Ablation
NCT00590668
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
NCT00274781
Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer
NCT00305617
T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases
NCT00589602
Clinical Implications of Peripheral Plaque Morphology
NCT00578422
Echocardiographic Assessment of Cardiovascular Changes in Long Term Space Flight
NCT00598598
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
NCT00400686
Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure
NCT00293150
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00268229
Prospective Randomized Study of Brain Protection During Aortic Arch Replacement
NCT00606190
Three Dimensional Imaging and Wireless Technologies to Enhance Medical Care in Space
NCT00598767
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
NCT00400517
Influenza Vaccination in Bone Marrow Transplantation
NCT00419224
The Effect of Fenoldopam in Solitary Partial Nephrectomy Surgery
NCT00743106
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
NCT00354393
Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer
NCT00401180
The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection
NCT00273377
GM-CSF in Patients With Pulmonary Alveolar Proteinosis
NCT00030056
Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts
NCT00583050
Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients
NCT00137748
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
NCT00276536
The Effect of Lipitor on Aortic Stenosis
NCT00590135
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL
NCT00274794
Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
NCT00289042
Combination Chemotherapy in Treating Patients With Multiple Myeloma
NCT00003493
Rituximab in Treating Patients With Multiple Myeloma
NCT00003554
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
NCT00003490
Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
NCT00583414
Biological Therapy in Treating Patients With Glioblastoma Multiforme
NCT00003185
ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement
NCT00298285
A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction
NCT00215124
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 38 |
| Phase 2 | 38 |
| Phase 3 | 22 |
| Phase 4 | 59 |
Therapeutic Areas
What is open in the The Cleveland Clinic pipeline
99 recruiting of 688 indexed (14% open); 437 completed (64%).
Phase mix: 81 late (III/IV) vs 76 early (I/II) (balanced across stages).
Top condition: Atrial Fibrillation (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
The Cleveland Clinic: open-pipeline peers nationwide
Peers matched on 688 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
The Cleveland Clinic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 688 trials (± recruiting share)
- Vanderbilt University Medical Center · 677 trials · 19% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
- Icahn School of Medicine at Mount Sinai · 708 trials · 23% recruiting
- Sanofi · 713 trials · 10% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Dana-Farber Cancer Institute · 14% recruiting · 781 trials
- ModernaTX · 14% recruiting · 90 trials
- Masonic Cancer Center, University of Minnesota · 14% recruiting · 249 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
Related
What to do with this The Cleveland Clinic page
688 registered trials is a research-attention snapshot, not an endorsement of The Cleveland Clinic or any single study.
- 99 of The Cleveland Clinic's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atrial Fibrillation is the condition The Cleveland Clinic studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atrial Fibrillation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. The Cleveland Clinic pipeline card: 688 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.